Belharra Therapeutics

Belharra Therapeutics, Inc. is a privately held drug discovery company whose novel photoaffinity-based chemoproteomics platform is disrupting the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharras proprietary noncovalent drug discovery engine is uniquely capable of identifying novel starting points for transformative medicines to address previously impossible-to-treat diseases and conditions. The companys next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Originating with Christopher G. Parker, Ph.D. and John Teijaro, Ph.D. at Scripps Research and pioneers in the...

Chemoproteomics,research,and drug discovery

Belharra therapeutics operates in the Biotechnology research industry.

Belharra therapeutics's revenue is 11m - 100m

Belharra therapeutics has 51 - 200 employees.